🇺🇸 FDA
Patent

US 9447419

RNAi-mediated inhibition of tumor necrosis factor α-related conditions

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 9447419 (RNAi-mediated inhibition of tumor necrosis factor α-related conditions) held by Arrowhead Pharmaceuticals, Inc. expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/7088, A61K31/713, A61P, A61P11/02